DALLAS, March 29, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring ARCA biopharma Inc. (Nasdaq:ABIO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/ABIO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
ARCA biopharma Inc. (ABIO) is a biopharmaceutical company whose principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate is Gencaro™ (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, which is under review by the U.S. Food and Drug Administration for chronic heart failure. ABIO has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. It is collaborating with Laboratory Corp. of America to develop the companion genetic test for Gencaro.
Message Board Search for ABIO: http://www.boardcentral.com/boards/ABIO
In the report, the analyst notes:
"ABIO shares surged last week after the Company announced it received a patent from the U.S. Patent and Trademark Office (USPTO) on methods of treating heart failure patients with bucindolol based on genetic testing. In a news release, ABIO president and CEO Michael R. Bristow stated: 'We are obviously pleased with the USPTO's issuance of this patent which we believe will extend our pharmacogenetic intellectual property protection around bucindolol and, if approved for marketing, provide Gencaro market exclusivity into 2025.'
"On March 25, 2010, the Company submitted a revised clinical study protocol for review under the FDA's Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of Gencaro in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro ... ABIO currently holds a fast track designation for Gencaro development in Genotype-defined heart failure population."
To read the entire report visit: http://www.stockpreacher.com/n/ABIO
See what investors are saying about ABIO at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com.
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.